All In Biotech

Drug Trial Radar · NCT04170283

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

955

Actual

Start

Jan 16, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Nov 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up after treatment. Information collected in this study will help health authorities better understand the long-term effects of zanubrutinib.

Conditions

  • B-cell Malignancies

Interventions

  • ZanubrutinibDrug

    Participants will receive a total dose of 320 mg daily, given either as 160 mg BID or 320 mg QD, or the last dose level received in the sponsor parent study.

  • TislelizumabDrug

    Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years

Locations

153 sites in 18 countries. Site status is shown where the registry gives one.

  • Banner Md Anderson Cancer Center

    Gilbert, Arizona

  • Carti Cancer Center

    Little Rock, Arkansas

  • Rocky Mountain Cancer Centers Centennial

    Centennial, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Florida Cancer Specialists Fort Myers

    Fort Myers, Florida

  • Scri Florida Cancer Specialists North

    St. Petersburg, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Forrest General Hospital Cancer Center

    Hattiesburg, Mississippi

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Summit Medical Group

    Florham Park, New Jersey

  • Atlantic Health System

    Morristown, New Jersey

  • Optum Medical Care, Pc.

    Westbury, New York

  • Duke University Hospital

    Durham, North Carolina

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Scri Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology Fort Worth Cancer Center

    Fort Worth, Texas

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Texas Oncology San Antonio Medical Center Usor

    San Antonio, Texas

  • Oncology and Hematology Associates of Southwest Virginia, Inc

    Roanoke, Virginia

  • University of Washington Seattle Cancer Alliance

    Seattle, Washington

  • Medical Oncology Associates

    Spokane, Washington

  • Paratus Clinical Research Woden

    Canberra, Australian Capital Territory, Australia

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Border Medical Oncology

    East Albury, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Brisbane Clinic For Lymphoma

    Greenslopes, Queensland, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinders Medical Centre

    Bedford PK, South Australia, Australia

  • Icon Cancer Centre Kurralta Park

    Kurralta Park, South Australia, Australia

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.